source
- India moves to suspend licenses of firms making substandard medicinesThe Indian government has proposed a rule that would immediately suspend the manufacturing licence of any company whose drug fails to meet quality standards. The initiative is intended to boost dr…
- FDA mandates label update for all GLP-1 drugs to warn of rare eye disease riskThe FDA issued a class‑wide labeling requirement for all approved GLP‑1 receptor agonists, adding a warning about non‑arteritic anterior ischemic optic neuropathy (NAION), a rare eye condition that…